Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia

Relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remains a therapeutic challenge. Loncastuximab tesirine is an antibody-drug conjugate against CD19, an antigen expressed in many B-cell malignancies. This open-label, single-arm, dose-escalation, dose-expansion study assessed t...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Adv
Asıl Yazarlar: Jain, Nitin, Stock, Wendy, Zeidan, Amer, Atallah, Ehab, McCloskey, James, Heffner, Leonard, Tomlinson, Benjamin, Bhatnagar, Bhavana, Feingold, Jay, Ungar, David, Chao, Grace, Zhang, Xiaoyan, Qin, Yajuan, Havenith, Karin, Kantarjian, Hagop, Wieduwilt, Matthew J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2020
Konular:
Lymphoid Neoplasia
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7013258/
https://ncbi.nlm.nih.gov/pubmed/32012214
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000767
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller